AIP
SPRO icon

Ameritas Investment Partners’s Spero Therapeutics SPRO Stock Holding History

Ameritas Investment Partners’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,713
Closed -$15K – 3220
2022
Q1 		$15K Hold
1,713
– – ﹤0.01% 2670
2021
Q4 		$27K Hold
1,713
– – ﹤0.01% 2503
2021
Q3 		$32K Hold
1,713
– – ﹤0.01% 2439
2021
Q2 		$24K Hold
1,713
– – ﹤0.01% 2655
2021
Q1 		$25K Hold
1,713
– – ﹤0.01% 2471
2020
Q4 		$33K Buy
1,713
+588
+52% +$9.17K ﹤0.01% 2225
2020
Q3 		$13K Hold
1,125
– – ﹤0.01% 2602
2020
Q2 		$15K Buy
1,125
+625
+125% +$7.02K ﹤0.01% 2512
2020
Q1 		$4K Hold
500
– – ﹤0.01% 2877
2019
Q4 		$5K Hold
500
– – ﹤0.01% 2905
2019
Q3 		$5K Hold
500
– – ﹤0.01% 2939
2019
Q2 		$6K Hold
500
– – ﹤0.01% 2929
2019
Q1 		$6K Hold
500
– – ﹤0.01% 2832
2018
Q4 		$3K Hold
500
– – ﹤0.01% 2916
2018
Q3 		$5K Hold
500
– – ﹤0.01% 2950
2018
Q2 		$7K Hold
500
– – ﹤0.01% 2901
2018
Q1 		$7K Hold
500
– – ﹤0.01% 2813
2017
Q4 		$6K Buy
+500
New +$6.14K ﹤0.01% 2851

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ameritas Investment Partners's SPRO Position: Q2 2022 in Review

Ameritas Investment Partners sold out of Spero Therapeutics (SPRO) in Q2 2022, closing a stake of 1,713 shares — an estimated $15K sold.

Ameritas Investment Partners first reported a position in SPRO in Q4 2017 and held it in 18 quarters. The position peaked at $33K in Q4 2020. 79 funds tracked by Wall St. Rank hold SPRO as of Q2 2022.

  • Ameritas Investment Partners reported no remaining Spero Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Ameritas Investment Partners sold 1,713 Spero Therapeutics shares in Q2 2022, an estimated $15K.
  • Ameritas Investment Partners first reported a position in Spero Therapeutics in Q4 2017 and held it in 18 quarters.
  • Ameritas Investment Partners's Spero Therapeutics position peaked at $33K in Q4 2020.
  • 79 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.